

Francesco Di Mario

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6314566/francesco-di-mario-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

56
papers

1,372
citations

20
h-index

36
g-index

59
ext. papers

1,593
ext. citations

3.5
avg, IF

4.02
L-index

#	Paper	IF	Citations
56	Pepsinogen II in gastritis and Helicobacter pylori infection.. <i>Helicobacter</i> , 2022 , e12872	4.9	0
55	Barrett's esophagus: results from an Italian cohort with tight endoscopic surveillance.. <i>Acta Biomedica</i> , 2022 , 93, e2022130	3.2	1
54	Low levels of G17 and Barrett esophagus: a clinical relationship.. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022 ,	5.9	
53	The natural history of symptomatic uncomplicated diverticular disease: a long-term follow-up study. <i>Annals of Gastroenterology</i> , 2021 , 34, 208-213	2.2	3
52	Abnormal Levels of Pepsinogen I and Gastrin 17 in a case of Møller Disease. <i>Acta Biomedica</i> , 2021 , 92, e2021207	3.2	1
51	The prevalence of symptomatic uncomplicated diverticular disease could be lower than expected: a single-center colonoscopy-based cohort study. <i>European Journal of Gastroenterology and Hepatology</i> , 2021 ,	2.2	3
50	Low Levels of Gastrin 17 are Related with Endoscopic Findings of Esophagitis and Typical Symptoms of GERD. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2021 , 30, 25-29	1.4	2
49	Functional Dyspepsia. <i>Acta Biomedica</i> , 2020 , 91, e2020069	3.2	2
48	Risk factors for endoscopic severity of diverticular disease of the colon and its outcome: a real-life case-control study. <i>European Journal of Gastroenterology and Hepatology</i> , 2020 , 32, 1123-1129	2.2	4
47	Diverticular Disease: a Gut Microbiota Perspective. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019 , 28, 327-337	1.4	13
46	International Consensus on Diverticulosis and Diverticular Disease. Statements from the 3rd International Symposium on Diverticular Disease. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019 , 28, 57-66	1.4	7
45	The DICA Endoscopic Classification for Diverticular Disease of the Colon Shows a Significant Interobserver Agreement among Community Endoscopists: an International Study. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019 , 28, 39-44	1.4	0
44	What's New in Diagnosing Diverticular Disease. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019 , 28, 17-22	1.4	1
43	The "DICA" endoscopic classification for diverticular disease of the colon shows a significant interobserver agreement among community endoscopists. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019 , 28, 23-27	1.4	1
42	Long-term efficacy of rifaximin to manage the symptomatic uncomplicated diverticular disease of the colon. <i>Journal of Investigative Medicine</i> , 2019 , 67, 767-770	2.9	10
41	Effectiveness and Safety of Pylera [®] in Patients Infected by Helicobacter Pylori: A Multicenter, Retrospective, Real Life Study. <i>Digestive Diseases</i> , 2018 , 36, 264-268	3.2	14
40	Efficacy and safety of a new nutraceutical formulation in managing patients with symptomatic uncomplicated diverticular disease: a 12-month, prospective, pilot study. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2018 , 27, 201-202	1.4	5

39	Relationship between Helicobacter pylori infection and GERD. <i>Acta Biomedica</i> , 2018 , 89, 40-43	3.2	7
38	Non-invasive method for the assessment of gastric acid secretion. <i>Acta Biomedica</i> , 2018 , 89, 53-57	3.2	3
37	New bismuth-containing quadruple therapy in patients infected with Helicobacter pylori: A first Italian experience in clinical practice. <i>Helicobacter</i> , 2017 , 22, e12371	4.9	27
36	The Sleeping Remnant. Effect of Roux-En-Y Gastric Bypass on Plasma Levels of Gastric Biomarkers in Morbidly Obese Women: A Prospective Longitudinal Study. <i>Obesity Surgery</i> , 2017 , 27, 1901-1905	3.7	3
35	Gastric Cancer as Preventable Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 1833-1843	6.9	119
34	Impact of diverticular inflammation and complication assessment classification on the burden of medical therapies in preventing diverticular disease complications in Italy. <i>Annals of Translational Medicine</i> , 2017 , 5, 320	3.2	5
33	A Primary-Care Interventional Model on the Diverticular Disease: Searching for the Optimal Therapeutic Schedule. <i>Journal of Clinical Gastroenterology</i> , 2016 , 50 Suppl 1, S93-6	3	2
32	Predictive value of the Diverticular Inflammation and Complication Assessment (DICA) endoscopic classification on the outcome of diverticular disease of the colon: An international study. <i>United European Gastroenterology Journal</i> , 2016 , 4, 604-13	5.3	24
31	Chronicles of a cancer foretold: 35 years of gastric cancer risk assessment. <i>Gut</i> , 2016 , 65, 721-5	19.2	43
30	Mesalazine for the Treatment of Symptomatic Uncomplicated Diverticular Disease of the Colon and for Primary Prevention of Diverticulitis: A Systematic Review of Randomized Clinical Trials. <i>Journal of Clinical Gastroenterology</i> , 2016 , 50 Suppl 1, S64-9	3	45
29	Serum levels of vitamin D are associated with the severity of the endoscopic appearance of diverticular disease of the colon according to DICA classification. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2016 , 25, 567-568	1.4	4
28	Is There a Role for Probiotics in Helicobacter pylori Therapy?. <i>Gastroenterology Clinics of North America</i> , 2015 , 44, 565-75	4.4	16
27	Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015. <i>Digestive and Liver Disease</i> , 2015 , 47, 903-12	3.3	77
26	Misleading results in the diagnosis of atrophic gastritis. <i>European Journal of Gastroenterology and Hepatology</i> , 2014 , 26, 1439-40	2.2	1
25	Gastric acid secretion: changes during a century. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2014 , 28, 953-65	2.5	23
24	Long-term treatment with mesalazine in patients with symptomatic uncomplicated diverticular disease. <i>Internal and Emergency Medicine</i> , 2012 , 7, 133-7	3.7	15
23	Quantification of serum levels of pepsinogens and gastrin to assess eradication of Helicobacter pylori. <i>Clinical Gastroenterology and Hepatology</i> , 2011 , 9, 440-2	6.9	20
22	Efficacy of 5-ASA in the treatment of colonic diverticular disease. <i>Journal of Clinical Gastroenterology</i> , 2010 , 44, 113-9	3	33

21	Proton pump inhibitors in GORD An overview of their pharmacology, efficacy and safety. <i>Pharmacological Research</i> , 2009 , 59, 135-53	10.2	126
20	Recurrent diverticulitis. <i>Journal of Clinical Gastroenterology</i> , 2008 , 42, 1130-4	3	15
19	A curcumin-based 1-week triple therapy for eradication of <i>Helicobacter pylori</i> infection: something to learn from failure?. <i>Helicobacter</i> , 2007 , 12, 238-43	4.9	84
18	Prevention of complications and symptomatic recurrences in diverticular disease with mesalazine: a 12-month follow-up. <i>Digestive Diseases and Sciences</i> , 2007 , 52, 2934-41	4	66
17	Diverticular disease in the elderly. <i>Digestive Diseases</i> , 2007 , 25, 151-9	3.2	102
16	Quality of life in uncomplicated symptomatic diverticular disease: is it another good reason for treatment?. <i>Digestive Diseases</i> , 2007 , 25, 252-9	3.2	60
15	Rescue therapies for the management of <i>Helicobacter pylori</i> infection. <i>Digestive Diseases</i> , 2006 , 24, 113-30	3.2	41
14	Use of mesalazine in diverticular disease. <i>Journal of Clinical Gastroenterology</i> , 2006 , 40 Suppl 3, S155-9	3	28
13	Usefulness of serum pepsinogens in <i>Helicobacter pylori</i> chronic gastritis: relationship with inflammation, activity, and density of the bacterium. <i>Digestive Diseases and Sciences</i> , 2006 , 51, 1791-5	4	43
12	Influence of antisecretory treatment with proton pump inhibitors on serum pepsinogen I levels. <i>Fundamental and Clinical Pharmacology</i> , 2005 , 19, 497-501	3.1	23
11	Recovery of gastric function after <i>Helicobacter pylori</i> eradication in subjects with body atrophic gastritis: prospective 4-year study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2005 , 20, 1664-6	4.6	6
10	Efficacy of mesalazine in the treatment of symptomatic diverticular disease. <i>Digestive Diseases and Sciences</i> , 2005 , 50, 581-6	4	88
9	Natural course of functional dyspepsia after <i>Helicobacter pylori</i> eradication: a seven-year survey. <i>Digestive Diseases and Sciences</i> , 2005 , 50, 2286-95	4	14
8	Clinical usefulness of serum pepsinogen II in the management of <i>Helicobacter pylori</i> infection. <i>Digestion</i> , 2004 , 70, 167-72	3.6	20
7	Use of lactoferrin for <i>Helicobacter pylori</i> eradication. Preliminary results. <i>Journal of Clinical Gastroenterology</i> , 2003 , 36, 396-8	3	30
6	Rabeprazole in a one-week eradication therapy of <i>Helicobacter pylori</i> : comparison of different dosages. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2003 , 18, 783-6	4	7
5	Prevention of acute NSAID-related gastroduodenal damage: a meta-analysis of controlled clinical trials. <i>Digestive Diseases and Sciences</i> , 2001 , 46, 1924-36	4	33
4	The clinical usefulness of serum pepsinogens, specific IgG anti-HP antibodies and gastrin for monitoring <i>Helicobacter pylori</i> treatment in older people. <i>Journal of the American Geriatrics Society</i> , 1996 , 44, 665-70	5.6	16

3	Gastric juice polymerase chain reaction: an alternative to histology in the diagnosis of <i>Helicobacter pylori</i> infection. <i>Helicobacter</i> , 1996 , 1, 159-64	4.9	18
2	Serum pepsinogen C: a useful marker of <i>Helicobacter pylori</i> eradication?. <i>Journal of Clinical Laboratory Analysis</i> , 1996 , 10, 1-5	3	9
1	Personality patterns and duodenal ulcer relapse under antisecretory treatment. <i>Canadian Journal of Psychiatry</i> , 1987 , 32, 777-8	4.8	2